Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study

Table 3

Definition of patients’ profile who could benefit from home-based intravenous immunoglobulin (Tegeline) by the investigators (safety population, ).

	Total number of responses of investigators (%)
Good understanding of patient on the advantages and inconveniences of home-based IVIg	82.6
Absence of acute renal failure	82.6
Autoimmune disease well diagnosed and requiring administration of regular IVIg	80.4
Good safety of Tegeline at the hospital (during the 3 last consecutive cycles at the hospital before starting treatment at home)	78.3
Choice of patient	76.1
Absence of chronic renal failure	76.1
Minimum number of IVIg cycles realized at the hospital considered necessary, before starting treatment at home	76.1
Collaboration with a service provider, one visiting nurse, or home hospitalization	69.6
No venous problem	69.6
Prescription of Tegeline by a hospital doctor	65.2
Minimum/maximum rate of flow considered necessary for the hospital, before the administration of Tegeline at home	45.7
Absence of thrombosis in veins for the Tegeline infusion	39.1
Presence of a third person at home	15.2
Well-balanced hypertension	10.9
Well-balanced cardiopathy	8.7
Collaboration with a home-hospitalization service provider	6.5
Well-balanced diabetes	4.3
Well-balanced coronary insufficiency	4.3